Publication Name	World Journal of Gastroenterology
Manuscript ID	12346
Country	China

Received	2014-07-03 09:34
Peer-Review Started	2014-07-03 19:24
First Decision by Editorial Office Director
Return for Revision	2014-08-14 11:48
Revised	2014-08-25 14:23
Publication Fee Transferred
Second Decision by Editor	2014-10-15 12:37
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2014-10-15 17:47
Articles in Press	2014-10-15 18:01
Edit the Manuscript by Language Editor	2014-10-25 21:51
Typeset the Manuscript	2015-02-02 08:16
Publish the Manuscript Online	2015-02-11 16:38

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Infectious Diseases
Manuscript Type	Retrospective Study
Article Title	Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B
Manuscript Source	Unsolicited Manuscript
All Author List	You-Wen Tan, Yun Ye, Guo-Hong Ge, Wei Zhao, Jian-He Gan, Yun Zhao, Zhi-Lin Niu, Dong-Jun Zhang, Li Chen, Xue-Jun Yu and Li-Jun Yang
Funding Agency and Grant Number	Funding Agency Grant Number Zhenjiang Municipal Science and Technology Commission SH2009016
Corresponding Author	Dr. You-Wen Tan, Associate Professor, Department of Liver Diseases, the Third Hospital of Zhenjiang Affiliated to Jiangsu University, No. 300, Daijiamen, Runzhou Distinct, Zhenjiang 212000, Jiangsu Province, China. tyw915@sina.com
Key Words	Chronic hepatitis B; Mutation; Tyrosine-methionine-aspartic acid-aspartic acid; Lamivudine; Virological breakthrough
Core Tip	Although tyrosine-methionine-aspartic acid-aspartic acid (YMDD) motif mutation is considered to occur secondary to the use of lamivudine, it has become increasingly apparent that YMDD mutations exist in nature. A total of 1268 chronic hepatitis B (CHB) patients were recruited from six centers. YMDD mutations were detected using Inno-Lipa hepatitis B virus (HBV) drug resistance line probe assay in 288 (22.71%) of the 1268 CHB patients. Our study demonstrated that lamivudine therapy was well tolerated by Chinese CHB patients with natural YMDD mutations and led to reductions in transaminase levels and HBV-DNA loss. However, breakthrough hepatitis tended to occur in patients with natural YMDD mutations.
Publish Date	2015-02-11 16:38
Citation	Tan YW, Ye Y, Ge GH, Zhao W, Gan JH, Zhao Y, Niu ZL, Zhang DJ, Chen L, Yu XJ, Yang LJ. Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B. World J Gastroenterol 2015; 21(7): 2089-2095
URL	http://www.wjgnet.com/1007-9327/full/v21/i7/2089.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i7.2089

Full Article (PDF)	WJG-21-2089.pdf
Full Article (Word)	WJG-21-2089.doc
Manuscript File	12346-Review.docx
Answering Reviewers	12346-Answering reviewers.pdf
Copyright License Agreement	12346-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	12346-Language certificate.pdf
Peer-review Report	12346-Peer reviews.pdf
Scientific Misconduct Check	12346-CrossCheck.jpg
Scientific Editor Work List	12346-Scientific editor work list.pdf